We are delighted to welcome NovaMechanics Ltd. as a new partner via the hop-on facility to the SMASH-HCM project: a major step towards developing solutions around Hypertrophic Cardiomyopathy (HCM).
With NovaMechanics on board, SMASH-HCM enters in silico drug repurposing and cardiovascular safety profiling, based on their expertise in cheminformatics, AI-driven drug discovery, and machine learning.
NovaMechanics will:
• work on two additional Work Packages on drug repurposing and cardiotoxicity prediction
• provides advanced computational methods combining omics, simulations, and predictive analytics
• work on the integration of drug discovery with SMASH-HCM’s digital twin for personalized treatment advice
By joining SMASH-HCM, NovaMechanics will be exposed to cutting-edge experimental data, simulation techniques, and benefit from the collaboration with SMASH-HCM Europe’s leading researchers in cardiovascular disease and digital health—enhancing their ability and impact within the area.
This collaboration strengthens both the scientific and applied extent of the project, accelerating faster and safer treatment methods for HCM.
We look forward to seeing SMASH-HCM grow with NovaMechanics on board, bringing in new energy, talent, and resources into our multi-disciplinary crew!